A Colton-supported NYU study published in Science Translational Medicine has identified impaired regulatory T cells as a key driver of Sjögren's disease — and found a promising existing drug as a potential therapy.
Yale's Colton Center for Autoimmunity has selected eleven faculty-led projects for 2024 funding, supporting breakthrough research into lupus, asthma, allergies, and other autoimmune diseases — with mentorship and commercialization support included.
Tel Aviv University's Colton Center has awarded nine interdisciplinary research grants in 2024, funding projects that explore autoimmune disease from organ-on-a-chip platforms to the role of stress and psychological factors in disease flare-ups.
A Colton-supported NYU study published in Science Immunology has discovered that the immune checkpoint protein PD-1 functions as a dimer — a finding that could transform drug design for both cancer and autoimmune disease.
Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.
Yale's Colton Center for Autoimmunity has awarded $750,000 to seven faculty-led projects advancing research into autoimmune and allergic diseases, with funding, mentorship, and commercialization support.
NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
Tel Aviv University's Colton Center for Autoimmunity joins a four-university consortium dedicated to finding cures for over 100 autoimmune diseases through big data analytics, multidisciplinary research, and international collaboration.
Yale's Colton Center for Autoimmunity has awarded 2022 grants to six projects spanning lupus, multiple sclerosis, pediatric OCD, and systemic sclerosis — all targeting new diagnostics, therapies, or disease mechanisms.
NYU Langone's Colton-backed Division of Rheumatology is taking a leading role in the NIH's $58 million AMP AIM program, driving research into lupus, psoriatic disease, Sjögren's disease, and the microbiome.
